WUMC-Cancer and Leukemia Group B

WUMC-癌症和白血病 B 组

• 批准号: 7480214
• 负责人: NANCY L BARTLETT
• 金额: $ 33.49万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-08 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7480214
• 关键词: 12p; 18q; 5' Untranslated Regions; ABCB1 gene; Academic Medical Centers; Accountability; Acetates; Acids; Acute Myelocytic Leukemia; Adenocarcinoma; Adjuvant; Adjuvant Study; Adopted; Adrenal Glands; Adult; Advanced Malignant Neoplasm; Adverse Drug Experience Reporting System; Allogenic; Amendment; American College of Radiology Imaging Network; American College of Surgeons Oncology Group; Aminocamptothecin; Androgen Antagonists; Androgen Receptor; Androgens; Animals; Antibodies; Antineoplastic Agents; Apoptotic; Appointment; Area; Arsenic Trioxide; Authorship; Award; Awareness; Back; Barrett Esophagus; Basic Science; Beds; Bexarotene; Bibliography; Biliary Tract Neoplasm; Bioinformatics; Biological Markers; Biopsy; Biostatistics Core; Blood Cells; Body of uterus; Bone Density; Bone Marrow; Bone Marrow Transplantation; Breast; Budgets; Cachexia; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Cancer Research Project; Cancer Therapy Evaluation Program; Cancer and Leukemia Group B; Candidate Disease Gene; Capital; Carboplatin; Carboplatin/Etoposide/Exisulind; Cardiovascular system; Caring; Categories; Cell Cycle; Cell Proliferation; Cells; Cellular biology; Chairperson; Charge; Chest; Cholangiocarcinoma; Cisplatin; Cisplatin/Cytarabine/Etoposide/Methylprednisolone; Classification; Clinic; Clinical; Clinical Pharmacists; Clinical Protocols; Clinical Research; Clinical Research Associate; Clinical Trials; Closure; Code; Collaborations; Colon; Colon Carcinoma; Colon, Rectum; Color; Colorectal; Colorectal Cancer; Commit; Committee Members; Committee Membership; Communication; Communities; Condition; Conflict (Psychology); Conflict of Interest; Conformal Radiotherapy; Consent; Consultations; Core Facility; Correlation Studies; Correlative Study; Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine; Cytogenetics; DNA Sequence; Daily; Data; Data Analyses; Data Collection; Data Quality; Databases; Development; Developmental Biology; Developmental Therapeutics Program; Diagnosis; Diarrhea; Diffuse Lymphoma; Discipline; Disease; Disorder by Site; Docetaxel/Estramustine; Docetaxel/Gemcitabine; Docetaxel/Irinotecan; Doctor of Medicine; Doctor of Philosophy; Dose; Doxorubicin/Gemcitabine; Doxorubicin/Topotecan; Doxorubicin/Vinblastine; Drug Kinetics; Eastern Cooperative Oncology Group; Economics; Education; Educational workshop; Elderly; Eligibility Determination; Enrollment; Ensure; Equipment and supply inventories; Etoposide; Evaluation; Excision; Extensive Stage; Faculty; Familiarity; Fellowship; Film; Fluorouracil; Fluorouracil/Interferon Alfa; Flutamide; Focus Groups; Follow-Up Studies; Fostering; Functional Imaging; Funding; Future; GG918; Gastrointestinal Lymphoma; Gemcitabine/Vinorelbine; Gene Mutation; Genes; Genetic; Genetic Polymorphism; Genitourinary system; Genomics; Genotype; Genus Cola; Goals; Grant; Group Meetings; Growth; Growth Factor; Guidelines; Gynecologic Oncology Group; Head; Health; Health behavior; Hematologic Neoplasms; Hematology; Hepatobiliary; Hepatocyte Growth Factor; Hereditary Malignant Neoplasm; Hodgkin Disease; Hormonal; Hospitals; Hour; Housing; Human; Human Resources; Hydrocortisone; Ifosfamide; Ifosfamide/Paclitaxel; Ifosfamide/Vinorelbine; Illinois; Image; Imaging Techniques; Imatinib mesylate; Incidence; Individual; Industry; Infusion procedures; Institutes; Institution; Interleukin-2; Investigation; Investigational Drugs; Irinotecan/UCN-01; Ketoconazole; Kidney; LY 335979; Label; Laboratories; Lead; Leadership; Left; Legal; Length; Leucovorin; Levamisole; Life; Ligands; Liposomal Doxorubicin; Liposomes; Localized; Lung; Lymphatic Irradiation; Lymphoma; Magnetic Resonance Imaging; Mails; Maintenance; Malignant Neoplasms; Malignant mesothelioma; Malignant neoplasm of esophagus; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Mammary Neoplasms; Manuscripts; Medical; Medical Oncologist; Medical Oncology; Medical center; Mesenchymal Stem Cells; Mesothelioma; Methods; Micrometastasis; Minority; Mission; Missouri; Mitoxantrone; Modality; Modeling; Modification; Molecular; Monitor; Monoclonal Antibodies; Mutation; N(delta)-acetylornithine, -isomer; N-dodecanoylglutamic acid, -isomer, sodium salt; NCI-Designated Cancer Center; Names; Navelbine ditartrate; Neoadjuvant Therapy; Neutropenia; Newly Diagnosed; Nodal; Non-Hodgkin' s Lymphoma; Non-Small-Cell Lung Carcinoma; Normal tissue morphology; Numbers; Nurses; Oncologist; Oncology Group; Online Systems; Ontology; Operative Surgical Procedures; Oral; Oropharyngeal; Outcome; Outcomes Research; Outpatients; P-Glycoprotein; P-Glycoproteins; Palliative Care; Pancreas; Participant; Pathogenesis; Pathology; Patient Care; Patient Monitoring; Patients; Peer Review; Perception; Performance; Peripheral; Pharmaceutical Preparations; Pharmacists; Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Pharmacologic Substance; Pharmacology; Pharmacy facility; Phase; Phase I Clinical Trials; Phase I/II Trial; Phase II Clinical Trials; Phase III Clinical Trials; Physicians; Pilot Projects; Placebos; Plastic Surgical Procedures; Point Mutation; Policies; Polyribosomes; Positioning Attribute; Positron-Emission Tomography; Preclinical Drug Development; Preparation; Principal Investigator; Printing; Procedures; Process; Prognostic Marker; Program Research Project Grants; Progressive Disease; Prostate; Prostate Cancer therapy; Prostatic Neoplasms; Protein Tyrosine Kinase; Protocol Compliance; Protocols documentation; Psychosocial Assessment and Care; Publications; Published Comment; Publishing; Quality of life; RNA Sequences; Radiation; Radiation Oncologist; Radiation Oncology; Radiation Therapist; Radiation Therapy Oncology Group; Radiation therapy; Radiology Specialty; Radiosurgery; Randomized; Rate; Receptor Protein-Tyrosine Kinases; Recombinants; Recommendation; Records; Recruitment Activity; Rectal Cancer; Recurrence; Refractory; Registries; Relapse; Reporting; Research; Research Design; Research Ethics Committees; Research Infrastructure; Research Personnel; Research Project Grants; Resected; Resources; Retinoids; Reverse Transcriptase Polymerase Chain Reaction; Review Committee; Risk; Roche brand of trastuzumab; Role; Running; SDZ-PSC-833; SGN-30; SU11248; Safety; Salvage Therapy; Sampling; Schedule; Science; Secure; Seeds; Series; Serious Adverse Event; Serum Markers; Services; Site; Solid; Solid Neoplasm; Source; Southwest Oncology Group; Specific qualifier value; Specimen; Speed; Staging; Stem Cell Research; Stem cell transplant; Stem cells; Stomach; Surgeon; Surgical Pathology; Surveys; System; TNFRSF8 gene; Tamoxifen; Tandem Repeat Sequences; Technology; Telefacsimile; Telephone; Temperature; Testing; Therapeutic; Therapeutic Studies; Therapy Clinical Trials; Thermometers; Thoracic Oncology; Thoracic Surgeon; Thoracic Surgical Procedures; Time; Tissue Procurements; Title; Topoisomerase Inhibitors; Topotecan; Toxic effect; Trainers Training; Training; Translating; Translational Research; Transplantation; Travel; Treatment Protocols; Tumor Burden; Tumor Suppressor Genes; Tyrosine; Tyrosine Kinase Inhibitor; Umbilical Cord Blood; United States; United States Food and Drug Administration; United States National Institutes of Health; Universities; Unresectable; Urology; Ursidae Family; Valspodar; Veterans; Visit; Washington; Week; Withdrawal; Woman; Work; Workload; Y 90 Ibritumomab Tiuxetan; ZD1839 (IRESSA); abstracting; alpha-difluoromethyl-DOPA, -isomer; alpha-methylornithine dihydrochloride, -isomer; analog; androgen independent prostate cancer; anticancer research; base; bevacizumab; bleomycin/dacarbazine/doxorubicin/vinblastine protocol; cancer care; cancer cell; cancer genetics; cancer imaging; cancer prevention; cancer statistics; cancer surgery; cancer type; celecoxib; chemosensitizing agent; chemotherapy; clinical conference; clinically relevant; cognitive function; cohort; concept; data management; database design; day; docetaxel; doxorubicin/etoposide/vinblastine protocol; embryonic stem cell; experience; expiration; falls; flavopiridol; follow-up; follower of religion Jewish; gastrointestinal; gemcitabine; hormone refractory prostate cancer; hormone therapy; human prostaglandin D2 receptor; human study; human subject; improved; inhibitor/antagonist; innovation; interest; irinotecan; leukemia; leukemia/lymphoma; lung small cell carcinoma; malignant breast neoplasm; medical specialties; melanoma; member; men; metropolitan; molecular imaging; molecular oncology; multidisciplinary; neuropsychiatry; novel; older patient; oncology; oxaliplatin; pilot trial; prescription document; prescription procedure; prevent; probation; prognostic; programs; prospective; quality assurance; receptor; research study; respiratory; response; rituximab; rosiglitazone; small molecule; statistical center; symposium; symptom management; translational study; trend; tumor; tumor immunology; uptake

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin's lymphoma, Hodgkin's lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials.

描述（改编自申请人的摘要）：自1986年以来，华盛顿大学一直是CALGB的主要成员机构。 在过去的五年里，华盛顿大学医学中心（WUMC）的癌症研究项目经历了巨大的增长。 巴恩斯犹太医院是圣路易斯最大的医院，每年诊断出5,400多名癌症患者，仍然是密苏里州东南部和伊利诺斯州南部的主要转诊中心。 2001年8月，WUMC的Siteman癌症中心（SCC）获得了NCI指定的癌症中心地位。 SCC为成功竞争NCI癌症中心支持补助金而开发的基础设施显著增强了我们开展临床癌症研究各个方面的能力，包括合作组试验。 我们最近扩大机构研究的努力将大大提高我们在下一个资助周期为CALGB贡献概念的能力，特别是在血液恶性肿瘤，胸部肿瘤和药物基因组学领域。 1998年至2002年期间，16名华盛顿大学的医生和研究助理在36个不同的CALGB科学和行政委员会任职。 WUMC研究人员主持了12项CALGB研究，包括非霍奇金淋巴瘤、霍奇金淋巴瘤、前列腺癌、间皮瘤的II期研究，以及几项药代动力学和药物基因组学相关科学研究。 另有六项研究正处于最后拟订阶段。 在此赠款期间，CALGB试验的应计费用继续增加，1998年至2001年，平均每年有183名患者登记参加治疗和非治疗试验。 接受治疗性试验的人数从1998年的61人增加到2001年的105人。 根据迄今为止的登记情况，预计2002年CALGB试验将增加312项，治疗性研究将增加136项。 下一个资助周期的计划包括1）所有当前WUMC研究者的继续参与，2）增加我们的I期研究者的参与，以促进CALGB内II期研究的发展，3）至少有五名额外的WUMC研究者参与CALGB活动，包括对GU肿瘤学，生活质量，干细胞移植和白血病，白血病相关科学和放射肿瘤学感兴趣的教师，以及5）继续努力增加CALGB试验的应计利润，特别是少数应计利润。